News Grower

Independent coverage of AI, startups, and technology.

Ars Technica Apr 15, 2026 at 14:11 Big Tech Rising Hot

What’s the deal with Alzheimer’s disease and amyloid?

For decades, scientists have concentrated on what now looks to be a blind alley.

Signal weather

Rising

Momentum is building quickly, so this card is a good early entry point into the topic.

By Jonathan M. Gitlin Original source
What’s the deal with Alzheimer’s disease and amyloid?

At the end of last month, a scientific journal pulled a research paper on Alzheimer's disease. The retraction came from Neurobiology of Aging, which removed a 2011 paper claiming to show that a version of a protein called amyloid-β was responsible for memory loss in Alzheimer's disease. On its own, that might not seem notable; bad papers can make it through peer review and are only caught after publication. But this wasn't an isolated case. Over the past few years, multiple studies arguing that amyloid-β is the central driver of Alzheimer's disease have been retracted. Some scientists have even been indicted for fraud over the issue. All the while, none of the drugs targeting this protein and its pathway have had any real clinical effect. Read full article Comments

Story map

Understand this topic fast

A quick entry into the story: why it matters now, who is involved, and where to go next for context.

Why it matters now

Fresh coverage with immediate momentum.
There are already 6 connected articles in the same storyline to continue from here.
The story keeps orbiting around Alzheimer, Amyloid, and Ars Technica, so the entity pages are the fastest way to build context.
Ars Technica already has 4 follow-up stories on the same theme.

Continue with this story

Follow the same topic through connected articles, entity pages, and active story threads.

Related articles

More stories that share tags, source, or category context.

More from Ars Technica

Fresh reporting and follow-up coverage from the same newsroom.

Open source page